Alterity Therapeutics (ATHE), a biotechnology company, on Tuesday, announced that the New Zealand Medicines and Medical Devices Safety Authority or Medsafe has given its approval for its Phase 2 clinical trial of ATH434. The trial aims to evaluate the potential of ATH434 as a disease-modifying treatment for Multiple System Atrophy or MSA, an uncommon and severely disabling Parkinsonian disorder.
Randomized, double-blind, and placebo-controlled clinical trial of ATH434 in individuals will investigate the impact of ATH434 treatment on imaging and protein biomarkers and will assess the clinical endpoints.
In the regular trading session on Friday, the stock closed at $2.6, down $0.06 or 2.26%. However, during the premarket trading, the stock is currently trading at $2.75, up $0.15 or 5.77%.
For comments and feedback: editorial@rttnews.com